Search Results - "Lanciego, Jose Luis"

Refine Results
  1. 1

    Prime time for G-protein-coupled receptor heteromers as therapeutic targets for CNS disorders: the dopamine D₁-D₃ receptor heteromer by Ferré, Sergi, Lluis, Carmen, Lanciego, José Luis, Franco, Rafael

    Published in CNS & neurological disorders drug targets (01-11-2010)
    “…A number of G-protein-coupled receptors (GPCRs) are currently under consideration as potential therapeutic targets for drugs acting in the central nervous…”
    Get more information
    Journal Article
  2. 2

    Alterations in Gene and Protein Expression of Cannabinoid CB2 and GPR55 Receptors in the Dorsolateral Prefrontal Cortex of Suicide Victims by García-Gutiérrez, María S., Navarrete, Francisco, Navarro, Gemma, Reyes-Resina, Irene, Franco, Rafael, Lanciego, Jose Luis, Giner, Salvador, Manzanares, Jorge

    Published in Neurotherapeutics (01-07-2018)
    “…Recent studies point to the cannabinoid CB 2 receptors (CB 2 r) and the non-cannabinoid receptor GPR55 as potential key targets involved in the response to…”
    Get full text
    Journal Article
  3. 3

    History and future challenges of the subthalamic nucleus as surgical target: Review article by Guridi, Jorge, Rodriguez‐Rojas, Rafael, Carmona‐Abellán, Mar, Parras, Olga, Becerra, Victoria, Lanciego, Jose Luis

    Published in Movement disorders (01-10-2018)
    “…ABSTRACT For many years the subthalamic nucleus had a poor reputation among neurosurgeons as a result of the acute movement disorders that develop after its…”
    Get full text
    Journal Article
  4. 4

    Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease by Armentero, Marie Therese, Pinna, Annalisa, Ferré, Sergi, Lanciego, José Luis, Müller, Christa E., Franco, Rafael

    Published in Pharmacology & therapeutics (Oxford) (01-12-2011)
    “…Several selective antagonists for adenosine A 2A receptors (A 2A R) are currently under evaluation in clinical trials (phases I to III) to treat Parkinson’s…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Cx3cr1‐deficiency exacerbates alpha‐synuclein‐A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease by Castro‐Sánchez, Sara, García‐Yagüe, Ángel J., López‐Royo, Tresa, Casarejos, Maria, Lanciego, José Luis, Lastres‐Becker, Isabel

    Published in Glia (01-08-2018)
    “…Parkinson's disease (PD) is the second most common neurodegenerative disorder characterized by the degeneration of dopaminergic neurons of the substantia nigra…”
    Get full text
    Journal Article
  7. 7

    Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys by Garbayo, Elisa, Ansorena, Eduardo, Lana, Hugo, Carmona-Abellan, María del Mar, Marcilla, Irene, Lanciego, José Luis, Luquin, María Rosario, Blanco-Prieto, María José

    Published in Biomaterials (01-12-2016)
    “…Abstract Glial cell line-derived neurotrophic factor (GDNF) remains the most potent neurotrophic factor for dopamine neurons. Despite its potential as…”
    Get full text
    Journal Article
  8. 8

    Cannabinoid Receptors CB1 and CB2 Form Functional Heteromers in Brain by Callén, Lucía, Moreno, Estefanía, Barroso-Chinea, Pedro, Moreno-Delgado, David, Cortés, Antoni, Mallol, Josefa, Casadó, Vicent, Lanciego, José Luis, Franco, Rafael, Lluis, Carmen, Canela, Enric I., McCormick, Peter J.

    Published in The Journal of biological chemistry (15-06-2012)
    “…Exploring the role of cannabinoid CB2 receptors in the brain, we present evidence of CB2 receptor molecular and functional interaction with cannabinoid CB1…”
    Get full text
    Journal Article
  9. 9

    Tadalafil crosses the blood–brain barrier and reverses cognitive dysfunction in a mouse model of AD by García-Barroso, Carolina, Ricobaraza, Ana, Pascual-Lucas, María, Unceta, Nora, Rico, Alberto J., Goicolea, Maria Aranzazu, Sallés, Joan, Lanciego, José Luis, Oyarzabal, Julen, Franco, Rafael, Cuadrado-Tejedor, Mar, García-Osta, Ana

    Published in Neuropharmacology (01-01-2013)
    “…Previous studies have demonstrated that cognitive function can be restored in mouse models of Alzheimer's disease (AD) following administration of sildenafil,…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12

    Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease by Garbayo, Elisa, Ansorena, Eduardo, Lanciego, Jose Luis, Blanco-Prieto, María Jose, Aymerich, María S.

    Published in Movement disorders (15-08-2011)
    “…Background: Glial cell‐derived neurotrophic factor is a survival factor for dopaminergic neurons and a promising candidate for the treatment of Parkinson's…”
    Get full text
    Journal Article
  13. 13

    Recent Insights into the Pathogenesis of Acute Porphyria Attacks and Increasing Hepatic PBGD as an Etiological Treatment by Jericó, Daniel, Córdoba, Karol M, Sampedro, Ana, Jiang, Lei, Joucla, Gilles, Cabanne, Charlotte, Lanciego, José Luis, Martini, Paolo G V, Berraondo, Pedro, Ávila, Matías A, Fontanellas, Antonio

    Published in Life (Basel, Switzerland) (01-11-2022)
    “…Rare diseases, especially monogenic diseases, which usually affect a single target protein, have attracted growing interest in drug research by encouraging…”
    Get full text
    Journal Article
  14. 14

    GPR40 activation leads to CREB and ERK phosphorylation in primary cultures of neurons from the mouse CNS and in human neuroblastoma cells by Zamarbide, Marta, Etayo-Labiano, Iñigo, Ricobaraza, Ana, Martínez-Pinilla, Eva, Aymerich, María S., Luis Lanciego, José, Pérez-Mediavilla, Alberto, Franco, Rafael

    Published in Hippocampus (01-07-2014)
    “…ABSTRACT GPR40, the free fatty acid receptor 1, is expressed strongly in the primate pancreas and brain. While the role of pancreatic GPR40 in glucose…”
    Get full text
    Journal Article
  15. 15

    Adeno-Associated Viral Vectors as Versatile Tools for Neurological Disorders: Focus on Delivery Routes and Therapeutic Perspectives by Fajardo-Serrano, Ana, Rico, Alberto J, Roda, Elvira, Honrubia, Adriana, Arrieta, Sandra, Ariznabarreta, Goiaz, Chocarro, Julia, Lorenzo-Ramos, Elena, Pejenaute, Alvaro, Vázquez, Alfonso, Lanciego, José Luis

    Published in Biomedicines (23-03-2022)
    “…It is without doubt that the gene therapy field is currently in the spotlight for the development of new therapeutics targeting unmet medical needs. Thus,…”
    Get full text
    Journal Article
  16. 16

    Interactions between Calmodulin, Adenosine A2A, and Dopamine D2 Receptors by Navarro, Gemma, Aymerich, Marisol S., Marcellino, Daniel, Cortés, Antoni, Casadó, Vicent, Mallol, Josefa, Canela, Enric I., Agnati, Luigi, Woods, Amina S., Fuxe, Kjell, Lluís, Carmen, Lanciego, Jose Luis, Ferré, Sergi, Franco, Rafael

    Published in The Journal of biological chemistry (09-10-2009)
    “…The Ca2+-binding protein calmodulin (CaM) has been shown to bind directly to cytoplasmic domains of some G protein-coupled receptors, including the dopamine D2…”
    Get full text
    Journal Article
  17. 17
  18. 18

    Two types of periglomerular cells in the olfactory bulb of the macaque monkey (Macaca fascicularis) by Liberia, Teresa, Blasco-Ibáñez, José Miguel, Nácher, Juan, Varea, Emilio, Lanciego, José Luis, Crespo, Carlos

    Published in Brain Structure and Function (01-07-2013)
    “…The olfactory bulb (OB) of mammals is the brain region that receives the sensory information coming from the olfactory epithelium. The entrance of the…”
    Get full text
    Journal Article
  19. 19

    Targeting CB1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson’s Disease by Martínez-Pinilla, Eva, Aguinaga, David, Navarro, Gemma, Rico, Alberto J., Oyarzábal, Julen, Sánchez-Arias, Juan A., Lanciego, José Luis, Franco, Rafael

    Published in Molecular neurobiology (01-08-2019)
    “…Cannabinoid CB 1 receptors (CB 1 R) and the GPR55 receptor are expressed in striatum and are potential targets in the therapy of Parkinson’s disease (PD), one…”
    Get full text
    Journal Article
  20. 20